BioCentury | Feb 12, 2019
Distillery Therapeutics

Neurology

...rat model of depression, the compound decreased depression-associated immobility compared with vehicle. Next steps by Neurolixis Inc....
...receptor agonist MN-305 in Phase II/III testing for anxiety and Phase II testing for insomnia. Neurolixis...
...testing for Parkinson's disease (PD). TARGET/MARKER/PATHWAY: Serotonin (5-HT1A) receptor LICENSING STATUS: Patent application filed by Neurolixis Inc....
BioCentury | Oct 7, 2013
Company News

Pierre Fabre, Neurolixis deal

...Pierre Fabre's Pierre Fabre Medicament division granted Neurolixis exclusive, worldwide rights to develop and commercialize serotonergic...
...upfront payment and will be eligible for undisclosed regulatory and clinical development milestones, plus royalties. Neurolixis...
...the compounds are expected to start in mid-2014. Laboratoires Pierre Fabre S.A. , Castres, France Neurolixis Inc....
Items per page:
1 - 2 of 2
BioCentury | Feb 12, 2019
Distillery Therapeutics

Neurology

...rat model of depression, the compound decreased depression-associated immobility compared with vehicle. Next steps by Neurolixis Inc....
...receptor agonist MN-305 in Phase II/III testing for anxiety and Phase II testing for insomnia. Neurolixis...
...testing for Parkinson's disease (PD). TARGET/MARKER/PATHWAY: Serotonin (5-HT1A) receptor LICENSING STATUS: Patent application filed by Neurolixis Inc....
BioCentury | Oct 7, 2013
Company News

Pierre Fabre, Neurolixis deal

...Pierre Fabre's Pierre Fabre Medicament division granted Neurolixis exclusive, worldwide rights to develop and commercialize serotonergic...
...upfront payment and will be eligible for undisclosed regulatory and clinical development milestones, plus royalties. Neurolixis...
...the compounds are expected to start in mid-2014. Laboratoires Pierre Fabre S.A. , Castres, France Neurolixis Inc....
Items per page:
1 - 2 of 2